Martek S&P MidCap
This article was originally published in The Tan Sheet
Executive Summary
Columbia, Md.-based firm will be added to Standard & Poor's MidCap 400 index after the close of trading March 1, Martek announces Feb. 25; the index covers roughly 7% of the U.S. equities market. CEO Henry Linsert says Martek's addition "should broaden the company's exposure to investors." Martek signed a license and supply agreement with Kellogg earlier this month (1"The Tan Sheet" Feb. 14, 2005, In Brief)...
You may also be interested in...
Martek/Kellogg agreement
Columbia, Md.-based firm announces a 15-year, non-exclusive docosahexaenoic acid (DHA) license and supply agreement with Kellogg Feb. 4, with the first DHA-fortified food product scheduled for launch in mid-2006. Kellogg will develop foods containing Martek's DHA and "must purchase, subject to certain exceptions, almost all of its DHA from Martek" for products in the U.S., as well as "display the Martek DHA logo on all product packages, print advertisements and certain other promotional materials." Martek has supply agreements with Mead Johnson and Nestle to provide DHA for infant formula...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.